{"id":47519,"date":"2012-08-01T13:02:40","date_gmt":"2012-08-01T12:02:40","guid":{"rendered":"https:\/\/www.btitrainingcenter.com\/a-randomized-clinical-trial-evaluating-plasma-rich-in-growth-factors-prgf-endoret-versus-hyaluronic-acid-in-the-short-term-treatment-of-symptomatic-knee-osteoarthritis\/"},"modified":"2026-04-08T12:19:18","modified_gmt":"2026-04-08T11:19:18","slug":"a-randomized-clinical-trial-evaluating-plasma-rich-in-growth-factors-prgf-endoret-versus-hyaluronic-acid-in-the-short-term-treatment-of-symptomatic-knee-osteoarthritis","status":"publish","type":"post","link":"https:\/\/www.btitrainingcenter.com\/it\/a-randomized-clinical-trial-evaluating-plasma-rich-in-growth-factors-prgf-endoret-versus-hyaluronic-acid-in-the-short-term-treatment-of-symptomatic-knee-osteoarthritis\/","title":{"rendered":"A randomized clinical trial evaluating plasma rich in growth factors (PRGF-Endoret) versus hyaluronic acid in the short-term treatment of symptomatic knee osteoarthritis"},"content":{"rendered":"

[vc_row gap=”20″ content_text_aligment=”left” row_background_lines=”no”][vc_column width=”2\/3″][vc_column_text css=””]<\/p>\n

Abstract<\/h3>\n
\n
\n

Purpose:\u00a0<\/strong>This multicenter, double-blind clinical trial evaluated and compared the efficacy and safety of PRGF-Endoret (BTI Biotechnology Institute, Vitoria-Gasteiz, Spain), an autologous biological therapy for regenerative purposes, versus hyaluronic acid (HA) as a short-term treatment for knee pain from osteoarthritis.<\/p>\n

Methods:\u00a0<\/strong>We randomly assigned 176 patients with symptomatic knee osteoarthritis to receive infiltrations with PRGF-Endoret or with HA (3 injections on a weekly basis). The primary outcome measure was a 50% decrease in knee pain from baseline to week 24. As secondary outcomes, we also assessed pain, stiffness, and physical function using the Western Ontario and McMaster Universities Osteoarthritis Index; the rate of response using the criteria of the Outcome Measures for Rheumatology Committee and Osteoarthritis Research Society International Standing Committee for Clinical Trials Response Criteria Initiative (OMERACT-OARSI); and safety.<\/p>\n

Results:\u00a0<\/strong>The mean age of the patients was 59.8 years, and 52% were women. Compared with the rate of response to HA, the rate of response to PRGF-Endoret was 14.1 percentage points higher (95% confidence interval, 0.5 to 27.6; P = .044). Regarding the secondary outcome measures, the rate of response to PRGF-Endoret was higher in all cases, although no significant differences were reached. Adverse events were mild and evenly distributed between the groups.<\/p>\n

Conclusions:\u00a0<\/strong>Plasma rich in growth factors showed superior short-term results when compared with HA in a randomized controlled trial, with a comparable safety profile, in alleviating symptoms of mild to moderate osteoarthritis of the knee.<\/p>\n<\/div>\n

Level of evidence:\u00a0<\/strong>Level I, randomized controlled multicenter trial.<\/p>\n<\/div>\n

[\/vc_column_text][vc_empty_space][\/vc_column][vc_column width=”1\/4″ css=”.vc_custom_1775643790226{margin-top: 78px !important;margin-right: 5% !important;margin-left: 30px !important;padding-right: 20px !important;padding-bottom: 20px !important;padding-left: 20px !important;background-color: #F6F6F6 !important;border-radius: 25px !important;}”]

[vc_column_text css=””]Accedi alla brochure di BTI:<\/em>[\/vc_column_text][vc_single_image image=”45401″ img_size=”medium” alignment=”center” onclick=”custom_link” img_link_target=”_blank” css=”” link=”https:\/\/www.btitrainingcenter.com\/wp-content\/uploads\/2021\/08\/6.-USA_ENTROA.pdf”]\n Accedi al pdf<\/span>\n <\/a><\/div><\/div>[\/vc_column][\/vc_row][vc_row][vc_column]\n Accedi all'articolo completo<\/span>\n <\/a>[\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Arthroscopy. 2012 Aug;28(8):1070-8.<\/strong>
\nThis multicenter, double-blind clinical trial evaluated and compared the efficacy and safety of PRGF-Endoret (BTI Biotechnology Institute, Vitoria-Gasteiz, Spain), an autologous biological therapy for regenerative purposes, versus hyaluronic acid (HA) as a short-term treatment for knee pain from osteoarthritis.<\/p>\n","protected":false},"author":2002,"featured_media":45401,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[157],"tags":[],"class_list":["post-47519","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicina-rigenerativa"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/posts\/47519","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/users\/2002"}],"replies":[{"embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/comments?post=47519"}],"version-history":[{"count":2,"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/posts\/47519\/revisions"}],"predecessor-version":[{"id":47521,"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/posts\/47519\/revisions\/47521"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/media\/45401"}],"wp:attachment":[{"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/media?parent=47519"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/categories?post=47519"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/tags?post=47519"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}